FY2024 Earnings Estimate for KYTX Issued By Leerink Partnrs

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Kyverna Therapeutics in a research note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($3.33) per share for the year, up from their prior estimate of ($3.54). The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.31) per share. Leerink Partnrs also issued estimates for Kyverna Therapeutics’ Q4 2024 earnings at ($0.87) EPS, FY2025 earnings at ($4.35) EPS, FY2026 earnings at ($4.73) EPS, FY2027 earnings at ($5.68) EPS and FY2028 earnings at ($6.03) EPS.

KYTX has been the subject of several other reports. HC Wainwright restated a “neutral” rating and issued a $7.00 price objective on shares of Kyverna Therapeutics in a research note on Thursday, September 19th. Wells Fargo & Company reduced their price target on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday. JPMorgan Chase & Co. lowered their price objective on Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. UBS Group began coverage on Kyverna Therapeutics in a research note on Thursday, October 10th. They set a “buy” rating and a $13.00 price objective for the company. Finally, RODMAN&RENSHAW upgraded shares of Kyverna Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $25.86.

Kyverna Therapeutics Stock Down 9.4 %

Shares of KYTX stock opened at $4.35 on Monday. Kyverna Therapeutics has a 12 month low of $4.30 and a 12 month high of $35.06. The company has a 50 day simple moving average of $5.46 and a two-hundred day simple moving average of $8.48.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings results on Wednesday, November 13th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.01. The business had revenue of $0.01 million for the quarter.

Hedge Funds Weigh In On Kyverna Therapeutics

Several institutional investors have recently bought and sold shares of KYTX. Geode Capital Management LLC lifted its stake in Kyverna Therapeutics by 19.0% in the 3rd quarter. Geode Capital Management LLC now owns 443,312 shares of the company’s stock worth $2,168,000 after purchasing an additional 70,714 shares in the last quarter. Barclays PLC grew its position in shares of Kyverna Therapeutics by 21.5% during the third quarter. Barclays PLC now owns 70,167 shares of the company’s stock valued at $343,000 after purchasing an additional 12,418 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Kyverna Therapeutics by 78.3% in the third quarter. Jane Street Group LLC now owns 39,193 shares of the company’s stock worth $192,000 after purchasing an additional 17,215 shares during the last quarter. Sphera Funds Management LTD. lifted its position in shares of Kyverna Therapeutics by 5.3% in the third quarter. Sphera Funds Management LTD. now owns 248,651 shares of the company’s stock worth $1,216,000 after buying an additional 12,622 shares in the last quarter. Finally, State Street Corp boosted its stake in Kyverna Therapeutics by 3.2% during the third quarter. State Street Corp now owns 326,192 shares of the company’s stock valued at $1,595,000 after buying an additional 10,244 shares during the last quarter. 18.08% of the stock is owned by hedge funds and other institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.